Search clinical trials for: TAK-577

Total 4954 results

Wakayama Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Takeda

Available

Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)
Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Takeda

Active, not recruiting

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (iinnovate-3)

Multiple Myeloma

Spain, United States, Australia, China, Korea, Republic of, Canada, France
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Chemotherapy | Malignant Tumor
Jin Chen-jin

Completed

Treatment Trial for Acute Central Serous Chorioretinopathy

Acute Central Serous Chorioretinopathy

China
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Colorectal Cancer

Taiwan
Takeda

Not yet recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand Disease (vWD)

Von Willebrand Disease (VWD)
University of Tasmania

Enrolling by invitation

TapTalkTest Project:Development of a Non-invasive Screening Test to Detect Risk of Alzheimer's Disease Pathology (TapTalkTest)

Dementia | Alzheimer Disease | Speech Disorders | Movement Abnormalities

Australia
The Eye Hospital of Wenzhou Medical University

Completed

Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy

Central Serous Choroidopathy

China
Oregon Research Institute

Recruiting

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

Aging | Mild Cognitive Impairment | Accidental Falls

United States
Al-Azhar University

Recruiting

A577-nm Pro -Yellow Laser In Treatment of Striae Rubra

Striae Rubra

Egypt
US Department of Veterans Affairs

Completed

Fitness and Daily Function in Adults

Cardiovascular Disease

United States
Afyonkarahisar Health Sciences University

Recruiting

Dual Task Gait Performance in Pediatric Oncology Patients

Pediatric Cancer

Turkey
St. Luke's-Roosevelt Hospital Center

Completed

Transplant and Addiction Project (TAP) - 1

Substance-Related Disorders | End Stage Liver Disease | End Stage Renal Disease

United States
University of Iceland
Uppsala University

Recruiting

The Lóa Study: A Brief Digital Intervention for Women With Intrusive Memories in the SAGA Cohort

Intrusive Memories of Traumatic Event(s)

Iceland
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Ospedale San Raffaele

Completed

Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD

Age-Related Macular Degeneration | Geographic Atrophy | Reticular Pseudodrusen

Italy
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Taiwan
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
The Lowy Medical Research Institute Limited

Active, not recruiting

MacTel Laser Study

Macular Telangiectasia

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Takeda

Terminated

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention-Deficit/Hyperactivity Disorder

United States
Takeda

Terminated

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes

United States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Japanese Healthy Adult Male

Japan
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Takeda

Completed

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses (TAK-438_107)

Gastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)

United Kingdom
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
Takeda

Completed

TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants

Healthy

United Kingdom
Ospedale San Raffaele
University of Rome Tor Vergata; University of Genova; Fondazione G.B. Bietti,...

Recruiting

Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration (PASCAL-RPD)

Macular Degeneration, Dry | Macular Degeneration, Senile | Laser Burn of Retina | Macular Degeneration Intermediate

Italy
University College, London

Not yet recruiting

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Medullary Thyroid Carcinoma | Bronchial and Thymic Neuroendocrine Tumour | Paraganglioma/ Phaeochromocytoma | Those Requiring Repeat Peptide Receptor Radionuclide Therapy
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Healthy Volunteers

United States

Search clinical trials for: TAK-577

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations